Genmab A/S (GMAB)
Company Info
Highlights
$12.15B
$1.84
10.52
1.09
$18.10B
$17.26B
$6.35B
$17.24 - $30.41
$29.56
0.33%
1.24
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Genmab A/S (GMAB) returned -7.24% year-to-date (YTD) and -32.87% over the past 12 months. Over the past 10 years, GMAB returned 8.41% annually, underperforming the S&P 500 benchmark at 10.46%.
GMAB
-7.24%
7.50%
-16.12%
-32.87%
-7.30%
8.41%
^GSPC (Benchmark)
-3.77%
7.44%
-5.60%
8.37%
14.12%
10.46%
Monthly Returns
The table below presents the monthly returns of GMAB, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -5.75% | 15.30% | -13.67% | 8.02% | -8.46% | -7.24% | |||||||
| 2024 | -13.29% | 0.58% | 7.71% | -7.42% | 1.84% | -10.89% | 12.57% | -1.73% | -12.30% | -8.45% | -3.67% | -2.93% | -34.45% |
| 2023 | -7.62% | -4.06% | 0.53% | 8.61% | -4.39% | -3.06% | 8.81% | -7.42% | -7.89% | -19.48% | 11.30% | 0.73% | -24.87% |
| 2022 | -13.85% | -1.82% | 8.13% | -2.76% | -14.01% | 7.40% | 9.63% | -0.36% | -9.47% | 19.86% | 20.83% | -8.92% | 7.13% |
| 2021 | -2.41% | -14.64% | -3.07% | 12.31% | 10.17% | 0.52% | 10.36% | 5.17% | -7.79% | 2.15% | -13.71% | 2.70% | -2.71% |
| 2020 | 3.94% | -1.85% | -6.98% | 14.82% | 25.24% | 11.22% | 0.89% | 10.44% | -3.05% | -8.06% | 14.71% | 5.31% | 82.09% |
| 2019 | -10.50% | 17.53% | 0.63% | -4.19% | 4.13% | 6.17% | -1.00% | 11.43% | -0.59% | 7.85% | 7.14% | -4.61% | 35.54% |
| 2018 | 10.82% | 13.23% | 4.24% | -6.96% | -24.70% | 0.86% | 12.27% | 0.96% | -9.30% | -13.21% | 12.55% | 7.08% | -0.61% |
| 2017 | 16.39% | 2.59% | -2.22% | 2.96% | 6.85% | 0.40% | 6.63% | 2.68% | -5.55% | -8.69% | -2.20% | -16.05% | -0.04% |
| 2016 | -6.80% | -1.12% | 12.60% | 6.05% | 22.29% | 1.25% | -0.16% | -12.56% | 7.34% | -2.55% | 3.84% | -4.22% | 23.73% |
| 2015 | 14.06% | 10.74% | 2.00% | 2.20% | 14.05% | -1.43% | 8.67% | -4.88% | 1.45% | 9.28% | 29.76% | 3.91% | 128.70% |
| 2014 | -0.46% | 14.12% | -6.21% | -11.18% | 7.88% | 5.61% | -4.45% | 0.20% | 4.21% | 4.28% | 13.44% | 17.67% | 49.72% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of GMAB is 10, meaning it’s performing worse than 90% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Genmab A/S (GMAB) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Genmab A/S. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Genmab A/S was 84.20%, occurring on Aug 8, 2011. Recovery took 538 trading sessions.
The current Genmab A/S drawdown is 60.26%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -84.2% | Jun 4, 2009 | 550 | Aug 8, 2011 | 538 | Sep 27, 2013 | 1088 |
| -63.1% | Sep 7, 2021 | 901 | Apr 8, 2025 | — | — | — |
| -48.37% | Sep 12, 2017 | 284 | Oct 25, 2018 | 272 | Nov 25, 2019 | 556 |
| -32% | Feb 24, 2020 | 16 | Mar 16, 2020 | 36 | May 6, 2020 | 52 |
| -30.41% | Dec 11, 2015 | 40 | Feb 9, 2016 | 36 | Apr 1, 2016 | 76 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Genmab A/S over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Genmab A/S, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 34.1% positive surprise.
Valuation
The Valuation section provides an overview of how Genmab A/S is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for GMAB, comparing it with other companies in the Biotechnology industry. Currently, GMAB has a P/E ratio of 10.5. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for GMAB compared to other companies in the Biotechnology industry. GMAB currently has a PEG ratio of 1.1. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for GMAB relative to other companies in the Biotechnology industry. Currently, GMAB has a P/S ratio of 0.6. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GMAB in comparison with other companies in the Biotechnology industry. Currently, GMAB has a P/B value of 2.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |